160388-55-6

Basic information

• Product Name: [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL
• Synonyms: [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL;benzenemethanol, 4-(1H-pyrazol-1-ylmethyl)-;[4-(1-pyrazolylmethyl)phenyl]methanol;[4-(pyrazol-1-ylmethyl)phenyl]methanol
• CAS NO: 160388-55-6
• Molecular Formula: C₁₁H₁₂N₂O
• Molecular Weight: 188.23
• Mol File: 160388-55-6.mol

Chemical Properties

• Melting Point: 51 °C
• Boiling Point: 377.913°C at 760 mmHg
• Flash Point: 182.355°C
• Appearance: /
• Density: 1.138g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• PKA: 14.34±0.10(Predicted)
• CAS DataBase Reference: [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL(160388-55-6)
• EPA Substance Registry System: [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL(160388-55-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 160388-55-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
[4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL is used as a research compound for exploring its potential biological activities and applications in the development of new pharmaceutical agents. Its unique structure allows for investigation into various therapeutic areas.
Used in Drug Development:
In the drug development industry, [4-(1H-PYRAZOL-1-YLMETHYL)PHENYL]METHANOL is utilized as a starting material or intermediate in the synthesis of novel drug candidates. Its distinctive structural elements can be leveraged to create innovative therapeutics with improved efficacy and safety profiles.

InChI:InChI=1/C11H12N2O/c14-9-11-4-2-10(3-5-11)8-13-7-1-6-12-13/h1-7,14H,8-9H2

Upstream product

• 26496-94-6 Ethyl 4-(bromomethyl)benzoate 
• 397328-86-8 methyl 4-((1H-pyrazol-1-yl)methyl)benzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 288-13-1 NH-pyrazole 
• 16473-35-1 4-(hydroxymethyl)benzyl chloride 

Downstream Products

• 160388-65-8 1-[[4-(chloromethyl)phenyl]methyl]-1H-pyrazole 
• 160388-58-9 4-(1H-pyrazol-1-ylmethyl)phenylacetonitrile 
• 222720-87-8 1-[[4-(bromomethyl)phenyl]methyl]-1H-pyrazole 

Relevant articles and documents

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

TRICYCLIC PYRAZOLOPYRIDINE COMPOUNDS

In one aspect this invention relates generally to compounds of Formula I and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where

PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS

In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.

HETEROCYCLIC DERIVATES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.

Non-steroidal antiinflammatory agents. Synthesis and enzyme inhibition of 2-[4-(heteroarylmethyl)phenyl]propanoic acids and analogues

Some 2-[4-(heteroarylmethyl)phenyl]propanoic acids and phenylacetic and benzoic analogues have been synthesized. All above acids were tested for their inhibitory activity on lipoxygenase and cyclooxygenase, in comparison with NDGA and tolmetin. 2-[4-(Thie